


REPLACED BY
ART 34 AMDT

29

Claims:

1. Use of a compound other than 9-(azabicyclo[2.2.2]octane-3-one)-6-chloro-9H-purine
5 having the ability to restore the apoptosis-inducing function of mutant p53 proteins,
which compound is selected from compounds having a structure according to the
formula I




15 wherein:

R1 is hydrogen or a methylene group, which can be double bonded, as
indicated by the broken line, or single bonded and linked to the nitrogen atom of an
amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a
purine, 8-azapurine, or benzimidazol residue, and;

20 A is an oxygen-containing moiety, either consisting of an oxygen atom being
double bonded, as indicated by the broken line, or a benzoyloxy group, with the proviso
that when A is a benzoyloxy group, then R1 is hydrogen,
for the preparation of a medicament for treating mutant p53 mediated diseases.

25 2. The use of claim 1, wherein the compound is selected from 2-(adenine-9-methylene)-
3-quinuclidinone, 2-methylene-3-quinuclidinone, 2-(-2-amino-3-chloro-5-
trifluoromethyl-1-methylaniline)-3-quinuclidinone, 2-(6-trifluoromethyl-4-
chlorobenzimidazole-1-methylene)-3-quinuclidinone, 2-(6-methoxypurine-9-methylene)-
3-quinuclidinone, 2-(8-azaadenine-9-methylene)-3-quinuclidinone, 1-azabicyclo
30 [2.2.2]oct-3-yl benzoate, 2-(5,6-dimethyl-benzimidazole-1-methylene)-3-quinuclidinone,
2-(8-azaadenine-7-methylene)-3-quinuclidinone, 2-(7-methylene-1,3-dimethyluric acid)-
3-quinuclidinone, or 2-(2,6-dichloro-9-methylenepurine)-3-quinuclidinone.


35 3. The use of claim 1 or 2, wherein the compound is selected from compounds having
the structure of the general formula I'



wherein

R₁ is a methylene group linked to the nitrogen atom of an amine-substituted phenyl group, a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and, more preferably R₁ is a methylene group linked to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue.

4. Use of a compound having the ability to restore the apoptosis-inducing function of mutant p53 proteins, which compound is selected from compounds having the structure of the general formula II



wherein


R₂ is chosen from the group consisting of hydrogen, methyl, or benzyl, for the preparation of a medicament for treating mutant p53 mediated diseases.

5. The use of claim 4, wherein the compound is 2-ethylene-4(3 H)-quinazolinone.

6. The use of anyone of the claims 1-5 together with a pharmaceutically acceptable carrier, diluent and/or excipient.

7. The use of anyone of the claims 1-6, wherein the mutant p53 mediated disease is cancer.

8. A method of treating a mutant p53 mediated disease, comprising administering to a mammal in need thereof a pharmaceutically efficient amount of a compound selected from compounds having a structure according to the formula I




wherein:

R₁ is hydrogen or a methylene group, which can be double bonded, as indicated by the broken line, or single bonded and linked to the nitrogen atom of an amine-substituted phenyl group, to a nitrogen atom contained in the ring structure of a purine, 8-azapurine, or benzimidazol residue, and;

A is an oxygen-containing moiety, either consisting of an oxygen atom being double bonded, as indicated by the broken line, or a benzoyloxy group, with the proviso that when A is a benzoyloxy group, then R₁ is hydrogen; or

a compound selected from compounds having the structure of the general formula II



wherein

R₂ is chosen from the group consisting of hydrogen, methyl, or benzyl.

9. The method of claim 8, wherein the mutant p53 mediated disease is cancer.